<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897611</url>
  </required_header>
  <id_info>
    <org_study_id>NABTT-0402 CDR0000462562</org_study_id>
    <secondary_id>U01CA062475</secondary_id>
    <secondary_id>NABTT-0402</secondary_id>
    <nct_id>NCT00897611</nct_id>
  </id_info>
  <brief_title>Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma</brief_title>
  <official_title>Identification of Hypermethylated Serum Tumor DNA in High Grade Glioma Patients and Correlation With Magnetic Resonance Imaging Findings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>North American Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying levels of tumor DNA in the samples of blood from patients with cancer may&#xD;
      help doctors find out whether the cancer has grown and how much.&#xD;
&#xD;
      PURPOSE: This laboratory study is comparing levels of tumor DNA with MRI and CT scan findings&#xD;
      to measure cancer growth in patients with grade III or grade IV malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Correlate changes in the level of serum tumor-specific DNA over time with changes in&#xD;
           brain tumor size as measured by serial MRI or CT scans in patients with grade III-IV&#xD;
           malignant gliomas.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Blood samples are collected from patients at baseline and every 2 months thereafter. Tumor&#xD;
      and nontumor plasma is extracted. Plasma samples are analyzed by polymerase chain reaction&#xD;
      (PCR) to assess the p16_ink4a, p73, and O ^6-MGMT gene promoter methylation profile.&#xD;
      Quantitative realtime PCR is performed on samples with tumor-specific DNA to determine the&#xD;
      plasma concentrations of each methylated tumor-specific gene and the total plasma&#xD;
      tumor-specific DNA concentration. Patients also undergo MRI or CT scans every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total plasma glioma-specific DNA concentration</measure>
    <time_frame>every 2 months until death</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor size</measure>
    <time_frame>every 2 months until death</time_frame>
  </primary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>High Grade Glioma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
    <other_name>blood collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <other_name>blood collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <other_name>CT scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <other_name>MRI scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant brain tumor&#xD;
&#xD;
               -  One of the following grade III or IV supratentorial gliomas:&#xD;
&#xD;
                    -  Anaplastic astrocytoma&#xD;
&#xD;
                    -  Anaplastic oligodendroglioma&#xD;
&#xD;
                    -  Glioblastoma multiforme&#xD;
&#xD;
          -  Newly diagnosed or recurrent disease&#xD;
&#xD;
          -  Planning to undergo anticancer therapy on a New Approaches to Brain Tumor Therapy&#xD;
             (NABTT) Consortium clinical trial&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart A. Grossman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyle Weaver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>November 29, 2012</last_update_submitted>
  <last_update_submitted_qc>November 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

